RO5424802 - alectinib - CH5424802
pathology | Demonstrated benefit and harm | k | |||
---|---|---|---|---|---|
lung cancer (metastatic) | versus chemotherapy No demonstrated result for efficacy | 1 trial | meta-analysis | ||
lung cancer (metastatic) | versus crizotinib alectinib superior to crizotinib in terms of PFS in ALEX, 2017 (1L patients) | 1 trial | meta-analysis |